Table 5. Characteristics of *S.* Enteritidis with novel *gyrA* mutation at codon 83 (Ser83Ile).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID | Source of isolate | MLVA type | Resistance to other than quinolones\*\* | MIC (mg/L) |
| Year | Specimen | Region\* | NAL | CIP | NOR |
| 51 | 2005 | Stool | BK | 5-5-10-null-3 | TET | ≥ 256 | 0.25 | 0.75 |
| 54 | 2005 | Stool | BK | 5-5-10-null-3 | TET | ≥ 256 | 0.19 | 0.5 |
| 57 | 2005 | Stool | NE | 5-5-10-null-3 | CTX | ≥ 256 | 0.094 | 0.25 |
| 64 | 2005 | Stool | S | 5-5-10-null-3 | - | ≥ 256 | 0.094 | 0.38 |
| 100 | 2006 | Stool | BK | 5-5-11-null-3 | TET | ≥ 256 | 0.38 | 1 |
| 108 | 2006 | Stool | BK | 5-5-10-null-3 | TET | ≥ 256 | 0.25 | 1 |
| 163 | 2007 | Stool | E | 5-5-10-null-3 | TET/SXT | ≥ 256 | 0.38 | 1 |
| 181 | 2007 | Blood | NE | 5-5-12-null-3 | TET | ≥ 256 | 0.38 | 1 |

MLVA, multiple-locus variable number tandem repeat analysis. MIC, minimum inhibitory concentrations. \*BK, Bangkok; C, Central provinces; E, Eastern provinces; N, Northern provinces; NE, Northeastern provinces; S, Southern provinces; W, Western provinces. \*\* CTX, cefotaxime; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline.